For this reason, the European LeukemiaNet recommendations on BCR‐ABL1 mutation testing in CML underlined the importance of using sequencing approaches rather than mutation‐specific assays, enabling screening for a limited number of mutations only. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.